Efficacy and safety of a mother-child technique for recanalization of chronic central venous occlusive disease in hemodialysis patients

医学 血液透析 闭塞的 疾病 心脏病学 内科学 重症监护医学
作者
Ziming Wan,Qiquan Lai,Yu Zhou,Bo Tu,Bo Hu,Fan He,Yong Xu,Hua Gan
出处
期刊:Journal of vascular surgery. Venous and lymphatic disorders [Elsevier BV]
卷期号:8 (4): 558-564 被引量:9
标识
DOI:10.1016/j.jvsv.2019.10.020
摘要

Abstract

Objective

There is no optimal treatment for central vein occlusive disease that remains a major contributor to vascular access impairment. This study aimed to review the outcomes of percutaneous treatment with a mother-child technique in the treatment of symptomatic central venous stenosis (CVS) and central venous occlusion (CVO) in patients on hemodialysis.

Methods

Data were collected retrospectively and included all consecutive patients with CVS or CVO who were treated with percutaneous angioplasty and stenting. The occlusive lesions were crossed using the mother-child technique with an angiographic catheter-in-guiding catheter system.

Results

A total of 36 patients with symptomatic CVS and 45 patients with total CVO were included. The average age and gender composition were similar between the two groups. Patients with CVO had higher prevalence of diabetic nephropathy than CVS (24.4% vs 5.6%; P < .05). Lesion success, device success, and procedural success were achieved in 36 (100%), 1 (100%), and 36 (100%) patients in the CVS group and in 43 (95.6%), 11 (100%), and 43 (95.6%) patients in the CVO group, respectively. There were no severe complications or procedure-related deaths in either group. During follow-up (median, 6 months), the primary patency rates were 89.7% (CVS) and 81.0% (CVO) at 6 months and were 54.2% (CVS) and 47.1% (CVO) at 12 months. The assisted primary patency rates were 100% (CVS) and 91.2% (CVO) at 6 and 12 months.

Conclusions

With extra backup support of the mother-child technique, percutaneous treatment provides an effective and safe method for recanalization of chronic venous occlusion in patients on hemodialysis.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小苏打真甜完成签到,获得积分10
1秒前
相宜发布了新的文献求助10
1秒前
科研通AI6.1应助洪吉飞采纳,获得10
1秒前
HAHA完成签到,获得积分10
1秒前
专注灵凡完成签到,获得积分10
1秒前
风趣的天真完成签到,获得积分10
2秒前
3秒前
鳄鱼蛋完成签到,获得积分10
3秒前
不想看文献完成签到 ,获得积分10
3秒前
Owen应助乐观黑米采纳,获得10
3秒前
3秒前
GB完成签到 ,获得积分10
4秒前
4秒前
新帅完成签到,获得积分10
4秒前
King完成签到 ,获得积分10
4秒前
5秒前
lilac完成签到,获得积分10
6秒前
i冯plus完成签到,获得积分10
6秒前
美丽萝莉完成签到,获得积分10
6秒前
拥月亮发布了新的文献求助10
7秒前
安静的乐松完成签到,获得积分10
7秒前
六也完成签到,获得积分10
7秒前
落后的小伙完成签到,获得积分20
7秒前
seven完成签到,获得积分10
7秒前
Annieqqiu完成签到 ,获得积分10
8秒前
LMW发布了新的文献求助10
9秒前
鲸鱼完成签到,获得积分10
9秒前
沟通亿心发布了新的文献求助10
10秒前
满意大门完成签到,获得积分10
10秒前
Ws路言完成签到,获得积分10
10秒前
量子星尘发布了新的文献求助10
10秒前
杨建航完成签到,获得积分10
11秒前
aki空中飞跃完成签到,获得积分10
11秒前
七子完成签到,获得积分0
11秒前
凡酒权发布了新的文献求助10
11秒前
MYMELODY完成签到,获得积分10
11秒前
YBurger完成签到,获得积分10
11秒前
科研小白完成签到,获得积分10
12秒前
12秒前
自信的汉堡完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 3000
Relation between chemical structure and local anesthetic action: tertiary alkylamine derivatives of diphenylhydantoin 1000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
Principles of town planning : translating concepts to applications 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6066740
求助须知:如何正确求助?哪些是违规求助? 7899062
关于积分的说明 16323539
捐赠科研通 5208490
什么是DOI,文献DOI怎么找? 2786324
邀请新用户注册赠送积分活动 1769033
关于科研通互助平台的介绍 1647818